

Central nervous system involvement in the antiphosph

British Journal of Rheumatology

42, 200-213

DOI: [10.1093/rheumatology/keg080](https://doi.org/10.1093/rheumatology/keg080)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Rheumatologic Diseases and Strokes. , 0, , 389-407.		0
2	Central nervous system lupus: a clinical approach to therapy. <i>Lupus</i> , 2003, 12, 935-942.	1.6	74
3	Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2004, 10, 89-126.	1.7	17
4	Lupus anticoagulant, Factor V Leiden, and methylenetetrahydrofolate reductase gene mutation in a lupus patient with cerebral venous thrombosis. <i>Clinical Rheumatology</i> , 2004, 23, 362-3.	2.2	17
5	Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 1239-1247.	6.7	84
6	Management of the neurological manifestations of APS—what do the trials tell us?. <i>Thrombosis Research</i> , 2004, 114, 489-499.	1.7	42
7	Primary Alveolar Hypoventilation Syndrome Complicated with Antiphospholipid Syndrome. <i>Internal Medicine</i> , 2005, 44, 987-989.	0.7	3
8	Hughes Syndrome, the Antiphospholipid Syndrome: A New Chapter in Neurology. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 465-486.	3.8	45
9	Management of neuropsychiatric lupus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 799-821.	3.3	74
10	Intracerebral arterial stenosis with neurological events associated with antiphospholipid syndrome. <i>Rheumatology</i> , 2005, 44, 948-949.	1.9	12
11	Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand?. <i>British Journal of Rheumatology</i> , 2005, 44, 434-442.	2.3	112
12	Intractable hiccup as the initial presenting feature of systemic lupus erythematosus. <i>Lupus</i> , 2005, 14, 406-408.	1.6	13
13	Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1490-1493.	0.9	65
14	Neuropsychiatric Lupus. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 273-298.	1.9	80
15	Antibodies to glutamate receptor subtype 3 (GluR3) are found in some patients suffering from epilepsy as the main disease, but not in patients whose epilepsy accompanies antiphospholipid syndrome or Sneddon's syndrome. <i>Autoimmunity</i> , 2005, 38, 417-424.	2.6	20
17	Geriatric Chorea. <i>Clinics in Geriatric Medicine</i> , 2006, 22, 879-897.	2.6	14
18	Cerebral Manifestations in the Antiphospholipid (Hughes) Syndrome. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 465-490.	1.9	77
19	Central nervous system involvement in systemic connective tissue diseases. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 311-317.	1.4	11

#	ARTICLE	IF	CITATIONS
20	Cerebral Disease Other than Stroke and Transient Ischemic Attack in Antiphospholipid Syndrome. , 2006, , 68-85.		1
21	Cerebral Ischemia in Antiphospholipid Syndrome. , 2006, , 53-67.		0
22	Psychiatric Manifestations as a Primary Symptom in Antiphospholipid Syndrome. International Journal of Immunopathology and Pharmacology, 2006, 19, 915-917.	2.1	9
23	Management of the antiphospholipid syndrome. Current Rheumatology Reports, 2006, 8, 114-120.	4.7	9
24	Atypical movement disorders in antiphospholipid syndrome. Movement Disorders, 2006, 21, 944-949.	3.9	50
25	Cognitive Deficits in Patients With Antiphospholipid Syndrome. Archives of Internal Medicine, 2006, 166, 2278.	3.8	112
26	Stenosis in Antiphospholipid Syndrome: A New Finding with Clinical Implications. Lupus, 2006, 15, 466-472.	1.6	15
27	Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis. Annals of the Rheumatic Diseases, 2006, 65, 525-528.	0.9	10
28	Vasculopathy and arterial stenotic lesions in the antiphospholipid syndrome. Rheumatology, 2007, 46, 907-910.	1.9	32
29	Lipoprotein (a) and apolipoprotein (a) in primary antiphospholipid syndrome. Clinical Biochemistry, 2007, 40, 317-320.	1.9	8
30	Neurological manifestations of the antiphospholipid syndrome: risk assessments and evidence-based medicine. International Journal of Clinical Practice, 2007, 61, 1561-1568.	1.7	20
31	Psychosis leading to the diagnosis of unrecognized systemic lupus erythematosus: a case report. Rheumatology International, 2007, 27, 883-885.	3.0	12
32	New insights into central nervous system lupus: A clinical perspective. Current Rheumatology Reports, 2007, 9, 116-124.	4.7	22
33	Antiphospholipid Syndrome and Cognition. Clinical Reviews in Allergy and Immunology, 2007, 32, 188-191.	6.5	10
34	Neurologic manifestations of the antiphospholipid syndrome: Integrating molecular and clinical lessons. Current Rheumatology Reports, 2008, 10, 67-73.	4.7	32
35	Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: Results from an international inception cohort study. Arthritis and Rheumatism, 2008, 58, 843-853.	6.7	177
36	The antiphospholipid syndrome. Best Practice and Research in Clinical Rheumatology, 2008, 22, 831-845.	3.3	15
37	Parkinsonism in a patient with antiphospholipid syndrome " Case report and literature review. Journal of the Neurological Sciences, 2008, 267, 166-169.	0.6	23

#	ARTICLE	IF	CITATIONS
38	Orofacial pain in the medically complex patient. , 2008, , 321-347.		1
39	Mania: Psychiatric Manifestations of the Antiphospholipid Syndrome. Psychosomatics, 2008, 49, 438-441.	2.5	21
40	Antiphospholipid syndrome: a systemic and multidisciplinary disease. International Journal of Rheumatic Diseases, 2008, 11, 97-108.	1.9	3
41	Bilateral Transverse Sinus Thrombosis Secondary to a Homozygous C677T MTHFR Gene Mutation. Genetic Testing and Molecular Biomarkers, 2008, 12, 363-365.	1.7	5
42	Abnormal Eye Movements Due to Radiographically Silent Ischaemia as a Presenting Sign of Antiphospholipid Syndrome. Neuro-Ophthalmology, 2008, 32, 87-92.	1.0	0
43	Ictus and antiphospholipid syndrome: How much is enough?. Autoimmunity, 2008, 41, 140-142.	2.6	4
44	Progressive multifocal leucoencephalopathy associated with lupus and methotrexate overdose. Lupus, 2008, 17, 1029-1032.	1.6	14
46	Complex movement disorders in primary antiphospholipid syndrome: A case report. Journal of the Neurological Sciences, 2009, 281, 101-103.	0.6	16
47	SLE-Related Longitudinal Myelitis with Favorable Outcome. Canadian Journal of Neurological Sciences, 2009, 36, 393-397.	0.5	6
48	The Antiphospholipid Syndrome as a Neurological Disease. Seminars in Arthritis and Rheumatism, 2010, 40, 97-108.	3.4	54
49	Perfusion MRI in neuro-psychiatric systemic lupus erthemathosus. Journal of Magnetic Resonance Imaging, 2010, 32, 283-288.	3.4	25
50	Neurological manifestations of antiphospholipid syndrome. European Journal of Clinical Investigation, 2010, 40, 350-359.	3.4	100
51	Anti-Î±-Internexin Autoantibody from Neuropsychiatric Lupus Induce Cognitive Damage via Inhibiting Axonal Elongation and Promote Neuron Apoptosis. PLoS ONE, 2010, 5, e11124.	2.5	38
52	Antiphospholipid syndrome, migraine and stroke. Lupus, 2010, 19, 555-556.	1.6	13
53	SÃndrome antifosfolipÃdico. , 2010, , 179-185.		0
54	Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus, 2010, 19, 406-411.	1.6	54
55	Antiphospholipid syndrome. Lancet, The, 2010, 376, 1498-1509.	13.7	916
56	Sindrome da anticorpi antifosfolipidi primaria (PAPS): descrizione di un caso clinico evoluto in lupus eritematoso sistemico. Italian Journal of Medicine, 2010, 4, 116-121.	0.3	0

#	ARTICLE	IF	CITATIONS
57	My�opathie lupique. Feuilles De Radiologie, 2011, 51, 66-69.	0.0	1
58	Spine Infection/Inflammation. Radiologic Clinics of North America, 2011, 49, 105-127.	1.8	94
59	Adverse Pregnancy Outcome in Antiphospholipid Antibodies Syndrome: Pathogenic Mechanisms and Clinical Management. , 0, , .		0
61	Clinical, Radiologic, and Therapeutic Analysis of 14 Patients with Transverse Myelitis Associated with Antiphospholipid Syndrome: Report of 4 Cases and Review of the Literature. Seminars in Arthritis and Rheumatism, 2011, 40, 349-357.	3.4	29
62	Pathological gambling and primary antiphospholipid (Hughes) syndrome: a unique neuropsychiatric association. Lupus, 2011, 20, 1086-1089.	1.6	6
63	OBSTETRIC ANTIPHOSPHOLIPID SYNDROME - A REVIEW. Fetal and Maternal Medicine Review, 2011, 22, 265-286.	0.3	0
64	Managing CNS involvement in systemic lupus erythematosus. International Journal of Clinical Rheumatology, 2011, 6, 547-567.	0.3	6
65	Seizures in Primary Antiphospholipid Syndrome: The Relevance of Smoking to Stroke. Clinical and Developmental Immunology, 2012, 2012, 1-7.	3.3	22
66	Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National Cohort Study. Lupus, 2012, 21, 338-345.	1.6	17
67	A Patient With Bipolar Disorder and Antiphospholipid Syndrome. Journal of Geriatric Psychiatry and Neurology, 2012, 25, 26-28.	2.3	7
68	Evolution of Antiphospholipid Antibody Syndrome. American Journal of Forensic Medicine and Pathology, 2012, 33, 303-304.	0.8	2
69	Heparin, antiphospholipid antibodies and the brain. Lupus, 2012, 21, 1039-1040.	1.6	13
70	Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology, 2012, 51, 157-168.	1.9	89
71	Early neuropsychiatric involvement in antiphospholipid syndrome. General Hospital Psychiatry, 2012, 34, 579.e1-579.e3.	2.4	9
72	Autonomic dysfunction and primary antiphospholipid syndrome: a frequent and frightening correlation?. International Journal of General Medicine, 2012, 5, 339.	1.8	6
73	Cognitive Dysfunction and Antiphospholipid Antibodies. Current Rheumatology Reports, 2012, 14, 95-98.	4.7	9
74	Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case�control study from a single center. Rheumatology International, 2012, 32, 129-135.	3.0	22
75	Cognitive impairment in antiphospholipid syndrome: evidence from animal models. Clinical Rheumatology, 2012, 31, 403-406.	2.2	16

#	ARTICLE	IF	CITATIONS
76	SÃndrome antifosfolÃpido. <i>Medicine</i> , 2013, 11, 1975-1980.	0.0	0
77	Increased Anti-Phospholipid Antibodies in Autism Spectrum Disorders. <i>Mediators of Inflammation</i> , 2013, 2013, 1-7.	3.0	35
78	Clinical Aspects of the Antiphospholipid Syndrome. , 2013, , 518-525.		2
79	A Case of Refractory Headache with Antiphospholipid Antibody Syndrome Improved by High-Intensity Warfarin Medication. <i>Journal of Rheumatic Diseases</i> , 2014, 21, 74.	1.1	0
80	InÃvivo evaluation of brain damage in the course of systemic lupus erythematosus using magnetic resonance spectroscopy, perfusion-weighted and diffusion-tensor imaging. <i>Lupus</i> , 2014, 23, 10-19.	1.6	64
81	Antiphospholipid Antibodies. , 2014, , 233-237.		0
82	Revisiting the Molecular Mechanism of Neurological Manifestations in Antiphospholipid Syndrome: Beyond Vascular Damage. <i>Journal of Immunology Research</i> , 2014, 2014, 1-9.	2.2	35
83	Isolated anti-Î²2Ãglycoprotein I antibodies in neurology: a frontier syndrome between multiple sclerosis and antiphospholipid syndrome?. <i>European Journal of Neurology</i> , 2014, 21, 901-906.	3.3	8
84	Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review. <i>Journal of Neurology</i> , 2014, 261, 1706-1714.	3.6	86
85	Movement Disorders Associated with General Medical Diseases. , 2014, , 1179-1207.		0
86	Bilateral Internal Carotid Artery Occlusion Associated with the Antiphospholipid Antibody Syndrome. <i>Case Reports in Neurology</i> , 2014, 6, 50-54.	0.7	5
87	Antiphospholipid antibodies as biomarkers in psychiatry: review of psychiatric manifestations in antiphospholipid syndrome. <i>Translational Developmental Psychiatry</i> , 2015, 3, 25452.	0.3	11
88	Intractable Headaches, Ischemic Stroke, and Seizures Are Linked to the Presence of Anti-Î²2GPI Antibodies in Patients with Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2015, 10, e0119911.	2.5	31
89	Twenty-year brain magnetic resonance imaging follow-up study in Systemic Lupus Erythematosus: Factors associated with accrual of damage and central nervous system involvement. <i>Autoimmunity Reviews</i> , 2015, 14, 510-516.	5.8	34
90	Difficult Clinical Situations in the Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2015, 17, 29.	4.7	18
91	Role of brain perfusion SPECT with 99mTc HMPAO in the assessment of response to drug therapy in patients with autoimmune vasculitis: A prospective study. <i>North American Journal of Medical Sciences</i> , 2015, 7, 135.	1.7	7
92	Hughes syndrome and Multiple sclerosis. <i>Lupus</i> , 2015, 24, 115-121.	1.6	18
93	Systemic lupus erythematosus diagnosis and management. <i>Rheumatology</i> , 2017, 56, kew401.	1.9	63

#	ARTICLE	IF	CITATIONS
94	Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?. Immunologic Research, 2017, 65, 230-241.	2.9	15
95	Frequency of psychological alterations in primary antiphospholipid syndrome: preliminary study. Lupus, 2018, 27, 837-840.	1.6	2
96	The cutaneous manifestations are significantly related to cerebrovascular in a Serbian cohort of patients with Hughes syndrome. Lupus, 2018, 27, 858-863.	1.6	6
97	Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy. Frontiers in Neurology, 2018, 9, 1001.	2.4	61
100	Clinical Aspects of Antiphospholipid Syndrome. , 2019, , 532-542.		0
101	Cognitive dysfunction and serum levels of brain-derived neurotrophic factor (BDNF) in primary anti-phospholipid syndrome (PAPS). Rheumatology, 2021, 60, 179-187.	1.9	6
102	Primary antiphospholipid antibody syndrome presenting with cortical venous sinus thrombosis. Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria, 2021, 30, 349.	0.1	0
103	Neurologic Manifestations of the Antiphospholipid Syndrome “an Update. Current Neurology and Neuroscience Reports, 2021, 21, 41.	4.2	26
104	Features of nervous system damage in antiphospholipid syndrome. Obstetrics, Gynecology and Reproduction, 2021, 15, 404-414.	0.5	0
105	Fatigue and Pain Measurements in Systemic Lupus Erythematosus. , 2021, , 303-335.		0
106	The Nervous System and Lupus. , 2011, , 727-746.		10
108	Cerebral venous thrombosis due to cryptogenic organising pneumopathy with antiphospholipid syndrome worsened by heparin-induced thrombocytopenia. BMJ Case Reports, 2013, 2013, bcr2013009500-bcr2013009500.	0.5	9
109	The challenges of antiphospholipid syndrome: experience from diagnosis to self-care. BMJ Case Reports, 2014, 2014, bcr2014205072-bcr2014205072.	0.5	3
110	Increased heterogeneity of brain perfusion is an early marker of central nervous system involvement in antiphospholipid antibody carriers. PLoS ONE, 2017, 12, e0182344.	2.5	2
111	Subtypes of Antiphospholipid Antibodies in Neurologic Disorders: An Observational Study. Current Rheumatology Reviews, 2018, 15, 59-66.	0.8	5
112	Antiphospholipid Syndrome (APS) - An Update on Clinical Features and Treatment Options. The Open Urology & Nephrology Journal, 2015, 8, 27-38.	0.2	1
113	A Rare Cause of Pulmonary Embolism and Seizure in a Young Man: Antiphospholipid Syndrome. Acta Cardiologica Sinica, 2016, 32, 247-9.	0.2	2
117	A Case of Superior Sagittal Sinus Thrombosis in a Patient with Systemic Lupus Erythematosus. Nishinon Journal of Dermatology, 2015, 77, 119-123.	0.0	0

#	ARTICLE	IF	CITATIONS
118	Ischemic and nonischemic manifestations of antiphospholipid syndrome. <i>Kazan Medical Journal</i> , 2015, 96, 61-69.	0.2	2
120	Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms. <i>Journal of Neuroinflammation</i> , 2021, 18, 259.	7.2	20
121	Neuro-Psychiatric Systemic Lupus Erythematosus. , 2005, , 311-329.		0
122	Non-MS Inflammatory Diseases of the CNS: MR Features in Addition to the White Matter. , 2005, , 331-341.		0
123	Is it necessary to perform connective tissue disorders laboratory tests when a patient experiences the first demyelinating attack?. <i>Journal of Research in Medical Sciences</i> , 2013, 18, 617-20.	0.9	0
124	Deep brain reversible encephalopathy: association with secondary antiphospholipid antibody syndrome. <i>American Journal of Neuroradiology</i> , 2007, 28, 76-8.	2.4	8
125	Anti-Phospholipid Syndrome Misdiagnosed As Multiple Sclerosis: A Case Report.. <i>Osmangaz Journal of Medicine</i> , 0, , .	0.1	0
126	Neuropsychiatric Manifestations of Antiphospholipid Syndrome – A Narrative Review. <i>Brain Sciences</i> , 2022, 12, 91.	2.3	9
127	Cognitive Impairment in Anti-Phospholipid Syndrome and Anti-Phospholipid Antibody Carriers. <i>Brain Sciences</i> , 2022, 12, 222.	2.3	2
128	Primary antiphospholipid syndrome in pediatrics: beyond thrombosis. Report of 32 cases and review of the evidence. <i>Pediatric Rheumatology</i> , 2022, 20, 13.	2.1	2
129	Proliferative Vasculopathy Associated With Antiphospholipid Antibodies in Patients With Neurological Symptoms. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	5
130	Role of Demyelination in the Persistence of Neurological and Mental Impairments after COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11291.	4.1	10
131	Neurologic Manifestations of Catastrophic Antiphospholipid Syndrome. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 589-600.	4.2	3
132	Diagnostic accuracy of the European League against rheumatism/American College of Rheumatology-2019 versus the Systemic Lupus International Collaborating Clinics-2012 versus the ACR-1997 classification criteria in adult systemic lupus erythematosus: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
133	Isolated intracranial hypertension without cerebral venous sinus thrombosis in APLA syndrome: an unique association. <i>International Journal of Neuroscience</i> , 0, , 1-4.	1.6	0